NetworkNewsBreaks – Adaptimmune Therapeutics Inc. (NASDAQ: ADAP) Featured in Mizuho Securities Research Report
Adaptimmune Therapeutics Inc. (NASDAQ: ADAP) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We initiate shares of ADAP with a Neutral and a $3 price target. We see the efforts to develop a TCR-based treatment for solid tumors as having reached an important milestone of human data and a path forward for lead programs, but the valuation, in our view, reflects the near term value of ADAP's technology.” To request access to the full report, visit http://nnw.fm/SaZ9d About Adaptimmune Therapeutics Inc. Adaptimmune is a clinical-stage biopharmaceutical company focused on the development…







